XTL Biopharmaceuticals

A biopharmaceutical company engaged in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases and psychedelic medicine.

Health Tech & Life Sciences

Public on TASE on Sep 2000
Public on NASDAQ on Sep 2005

Public Ramat Gan, Israel Founded 1993

Last updated 2026-07-27

Went public on London Stock Exchange (XTL), Sep 2000
Raised $28M Follow-on PO, May 2006
Raised $5.8M Follow-on PO, Jun 2021

Total raised

$59.5M

Last: PIPE 2026-06

Stage

Public

Founded

1993

Headcount

Ramat Gan, Israel

Sector

Health Tech & Life Sciences

Website ↗LinkedIn ↗Registrar ID: 520039470 (XTL Biopharmaceuticals Ltd.)

About

XTL Biopharmaceuticals Ltd. is an Israeli biopharmaceutical company focused on the acquisition and development of pharmaceutical drugs for unmet clinical needs. The company's pipeline includes hCDR1 for systemic lupus erythematosus and Sjogren's syndrome, and recombinant human erythropoietin (rHuEPO) for multiple myeloma. More recently, XTL Biopharmaceuticals has strategically shifted its core business to psychedelic medicine through the acquisition of Psyga Bio Ltd., focusing on developing clinical-stage biopharmaceutical assets targeting severe mental health disorders.

Funding history · 7 rounds · $59.5M total

9 events/rounds · $59.5M Total Funding: $2.2M in Private Equity, $101.3M in Public Equity

Jun 2021

Follow-on PO $5.8M EDGAR filing SEC-EDGAR filing SEC-EDGAR 42…

Feb 2017

Follow-on PO $2.5M EDGAR filing SEC-EDGAR filing SEC-EDGAR 42…

Apr 2015

Follow-on PO $4.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR 42…

Sep 2014

Follow-on PO Undisclosed EDGAR filing SEC-EDGAR filing SEC-EDGAR 42…

May 2006

Follow-on PO $28.0M EDGAR filing SEC-EDGAR filing SEC-EDGAR 42…

Jul 2003

Undisclosed Round $2.2M bioworld.com ↗

★ Israel Healthcare VenturesShore Capital Group

Aug 2000

Follow-on PO $17.0M xtlbio.com ↗

★ Large institutional investors

Headcount over time

10 employees (2026-09) · 1 point

Offices

Ramat Gan, Israel · HQ / main office

Q&A

What is XTL Biopharmaceuticals' primary focus?: XTL Biopharmaceuticals is an Israeli biopharmaceutical company focused on the acquisition and development of pharmaceutical drugs for unmet clinical needs, with a recent strategic shift towards psychedelic medicine.
When did XTL Biopharmaceuticals go public on the London Stock Exchange?: XTL Biopharmaceuticals went public on the London Stock Exchange in September 2000, raising $44,000,000 with a valuation of $230,000,000.
When did XTL Biopharmaceuticals go public on NASDAQ?: XTL Biopharmaceuticals went public on NASDAQ in September 2005.
Who is the current CEO of XTL Biopharmaceuticals?: Mr. Noam Band was named the new Chief Executive Officer of XTL Biopharmaceuticals in April 2025.
What was a significant acquisition completed by XTL Biopharmaceuticals in 2026?: XTL Biopharmaceuticals completed the acquisition of Psyga Bio Ltd. in June 2026, establishing a psychedelic biotechnology platform.
What was the latest funding round for XTL Biopharmaceuticals?: XTL Biopharmaceuticals completed a PIPE funding round in June 2026, raising $1,500,000.
What is the current employee count for XTL Biopharmaceuticals?: XTL Biopharmaceuticals has 10 employees, which falls into the 1-10 employee bucket.
What was a recent acquisition by XTL Biopharmaceuticals in the autism market?: In January 2026, XTL Biopharmaceuticals acquired 85% of NeuroNOS, a subsidiary of Beyond Air, to enter the autism market.

Team · 12

Noam Band

Chief Executive Officer and Director

Segal Niv CPA

Chief Financial Officer

Shlomo Spokone Shalev

Chairman

Osnat Hillel Fain

Independent Non-Executive & External Director

Alexander Rabinovich

Non-Executive Director

Iris Shapira Yalon

Independent Non-Executive & External Director

Murray Urowitz